SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
疾风少年
Lv4
1
630 积分
2022-12-01 加入
最近求助
最近应助
互助留言
原发性肺癌罕见靶点靶向治疗中国临床诊疗指南(2024版)
4天前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
21天前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
21天前
已完结
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
23天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
1个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
1个月前
已完结
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
1个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Understanding the complexity of p53 in a new era of tumor suppression
1个月前
已完结
没有进行任何应助
感谢,速度真快
1个月前
感谢,点赞
1个月前
感谢,点赞
1个月前
感谢,点赞
1个月前
感谢,点赞
5个月前
标题有问题【积分已退回】
5个月前
无法下载
5个月前
点赞,速度真快
7个月前
帮大忙了,么么哒
7个月前
感谢,速度真快
7个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论